Top Section/Ad
Top Section/Ad
Most recent
Weak or half-hearted response to Greenland threats will leave markets crumbling
Over the last week the US president has pushed to make homes and consumer credit more affordable but these policies risk unintended consequences
Issuance volumes may be high but demand is even higher. Credit issuers in particular should take full advantage
Hounding the Fed does not make the US bond market more attractive
More articles/Ad
More articles/Ad
More articles
-
Italian prime minister-designate Mario Draghi must walk a knife-edge if he is to form a government and present a national recovery and resilience plan. If he takes too hard a line the mill of Italian politics will chew him up and spit him out. If he is too quick to compromise, the EU’s life as a giant bond issuer may be shorter than hoped. -
Retail shareholders have been excluded from a string of recent hot IPOs on the London Stock Exchange. This does little to dispel accusations that financial markets are the preserve of the elite.
-
Chinese regulators have made a long overdue move to reduce the number of boards at the Shenzhen stock exchange. That points to a greater commitment towards streamlining the country’s sometimes confounding capital markets.
-
Volumes in Asia’s loan market have slumped in recent years, with the pandemic only adding to the pressure. However, the biggest challenges for banks and borrowers are only just starting to emerge and they will test the industry's resilience.
-
The extraordinary price action in GameStop, AMC Entertainment and others' shares last week is surely leading nervous CFOs all over the world to get an at-the-money rights issue signed off, in case they win the attention of Reddit's WallStreetBets crowd and can raise equity at giddy multiples. But this is like hoping for a winning lottery ticket. For firms in the most Covid-addled sectors, a private approach will be their best shot at financing a turnaround.
-
Global equity markets were propelled to new all-time highs at the end of last year when various drug companies announced that they were close to releasing vaccines to combat the Covid-19 pandemic. However, with the vaccine roll-out slow, new mutant variants of the virus raging and governments striking a sombre tone, investors need to prepare for the fact that they may have bought in haste.
